TriangleNCT01715285 · OUTCOME
Time to Subsequent Therapy for Prostate Cancer
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 66 months
What was measured
Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer.
Analysis population: ITT analysis set included all subjects randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received.
Groups in this outcome
Abiraterone Acetate+Prednisone+ADT
Participants received abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) was administered.
Placebo + ADT
Participants received placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT was administered.
| Group | Source count |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | 597 |
| Placebo + ADT | 602 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Abiraterone Acetate+Prednisone+ADT | 54.87 | Not reported | 46.42 | NA | Here 'NA' indicates that the upper limit of 95% CI was not estimated due to lesser number of events. |
| Placebo + ADT | 21.22 | Not reported | 18.56 | 23.49 | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Here 'NA' indicates that the upper limit of 95% CI was not estimated due to lesser number of events.
- group Id
- OG000
- lower Limit
- 46.42
- upper Limit
- NA
- value
- 54.87
- group Id
- OG001
- lower Limit
- 18.56
- upper Limit
- 23.49
- value
- 21.22
- denoms
- counts
- group Id
- OG000
- value
- 597
- group Id
- OG001
- value
- 602
- units
- Participants
- description
- Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) was administered.
- id
- OG000
- title
- Abiraterone Acetate+Prednisone+ADT
- description
- Participants received placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT was administered.
- id
- OG001
- title
- Placebo + ADT
- param Type
- MEDIAN
- population Description
- ITT analysis set included all subjects randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received.
- reporting Status
- POSTED
- time Frame
- Up to 66 months
- title
- Time to Subsequent Therapy for Prostate Cancer
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice